 |
0 Diseases |  |
0 Trials |
|
0 Trials |  |
1 News |  |
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Apr 29, 2024
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Oct 12, 2022
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Oct 12, 2022
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Jul 12, 2022
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jun 21, 2022
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022 Trial completion date: Jun 2022 --> Dec 2022 | Trial primary completion date: Jun 2022 --> Dec 2022
- | INO-5401 / Inovio
ダナファーバー #ASCO22 発表（1）：【1】膠芽腫に対する免疫療法薬（INO-5401とセミプリマブ）併用は安全かつ有望【2】患者記入型のスクリーニングツールが遺伝性がん（リンチ症候群）リスクの検出率を高める可能性 https://t.co/aT0kam8beq #脳腫瘍 #リンチ症候群 (Twitter) - Jun 13, 2022
- | INO-5401 / Inovio, suratadenoturev (OBP-301) / Oncolys BioPharma, FHD-609 / Foghorn Therap
Journal: Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. (Pubmed Central) - Jun 11, 2022
We identified TP53-modulating drugs to be possibly effective in 20-26% of patients, followed by the Wnt signaling pathway inhibitors (15%), Telomelysin and INO5401 (13%), FHD-609 (13%), etc. According to our data, 67% of ACC patients exhibited genomic alterations that might be targeted by FDA-approved drugs or drugs being tested in current clinical trials. Although there are not many current therapy options directly targeting reported ACC alterations, this study identifies emerging options that could be tested in clinical trials.
- |||| Libtayo (cemiplimab) / Sanofi, Regeneron, rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Combination therapy: First- @delaFuenteNOnc is a co-author in the oral presentation “Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma”. https://t.co/ckR8MRLpzZ (Twitter) - Jun 1, 2022
- Libtayo (cemiplimab) / Regeneron, rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4445;
P1/2
Pre-treatment gene expression signatures in MGMT-unmethylated patients were statistically associated with OS18. Overall, INO-5401 elicits antigen-specific T cells that can infiltrate GBM tumors.
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Jan 18, 2022
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Overall, INO-5401 elicits antigen-specific T cells that can infiltrate GBM tumors. Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jan 10, 2022
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022
- Libtayo (cemiplimab) / Sanofi, Regeneron, rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
INO-5401 and INO-9012 Delivered Intramuscularly (IM) with Electroporation (EP) in Combination with Cemiplimab (REGN2810) in Newly Diagnosed Glioblastoma (Independence Ballroom (Marriott Marquis)) - Oct 1, 2021 - Abstract #SITC2021SITC_18;
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Jun 3, 2021
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial completion date: Dec 2021 --> Jun 2022 | Trial primary completion date: Dec 2021 --> Jun 2022 Trial primary completion date: Jul 2021 --> Dec 2021
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jun 3, 2021
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Trial primary completion date: Jul 2021 --> Dec 2021 Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Apr 22, 2021
P1b, N=44, Recruiting, Sponsor: University of Pennsylvania
Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Jun 2021 --> Dec 2021 Not yet recruiting --> Recruiting
- ||| INO-5401 / Inovio
@InovioPharma #INO5401 will save many people suffering from prostate cancer from painful chemotherapy and will extend their life for many years. @POTUS @DrWoodcockFDA @elonmusk @WHO @BernieSanders @DrBiden @AP @vivek_murthy @CEPIvaccines @VP @CDCDirector it’s the simple truth! (Twitter) - Feb 7, 2021
- ||| INO-5401 / Inovio
BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers #inovio $ino (Twitter) - Nov 19, 2020
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Nov 16, 2020
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Jan 2021 --> Jun 2021 | Trial primary completion date: Jan 2021 --> Jun 2021
- |||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 (Twitter) - Nov 4, 2020
- ||| #Inovio $INO #INO4800 #INO5401 #GBM data on the 19th #VIN #AIN data #ZIKA data #SNO2020 #VGX3100 $REGN (Twitter) - Nov 2, 2020
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
[VIRTUAL] INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma () - Oct 24, 2020 - Abstract #SNO2020SNO_268;
P1/2
Overall survival is encouraging. Clinical trial information: NCT03491683.
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment change, Trial initiation date, Trial primary completion date, Combination therapy, BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Oct 14, 2020
P1b, N=44, Not yet recruiting, Sponsor: University of Pennsylvania
Clinical trial information: NCT03491683. N=28 --> 44 | Initiation date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2025
- || INO-9012 / Inovio, INO-5401 / Inovio
Dr. Reardon on the Potential Utility of INO-5401 and INO-9012 in Glioblastoma https://t.co/d59T21wSyY via @onclive (Twitter) - Aug 19, 2020
- | INO-5401 / Inovio
INO-5401 coming soon! (Twitter) - May 13, 2020
- ||| #Inovio #GBM #BARDA #CEPI #cepivaccines #INO5401 #COVID19 #INO4800 #oncology #ASCO20 (Twitter) - May 13, 2020
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Trial completion date, Trial primary completion date, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Apr 29, 2020
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=28 --> 44 | Initiation date: Sep 2020 --> Dec 2020 | Trial primary completion date: Sep 2020 --> Dec 2025 Trial completion date: Sep 2020 --> Dec 2021 | Trial primary completion date: Mar 2020 --> Jul 2021
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1 trial, Combination therapy, BRCA Biomarker: INO 5401 Vaccination in BRCA1/2 Mutation Carriers (clinicaltrials.gov) - Apr 28, 2020
P1b, N=28, Not yet recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
[VIRTUAL] INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results. (Poster Board 5) - Feb 27, 2020 - Abstract #ASCO2020ASCO_166;
P1/2
OS18 data will be presented later this year. Research Funding: Inovio
- Libtayo (cemiplimab) / Sanofi, Regeneron, INO-9012 / Inovio, INO-5401 / Inovio
An Open-Label, Multi-center Trial of INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination with Cemiplimab in Subjects with Newly-Diagnosed Glioblastoma (GBM) (Prince George's Exhibition Halls AB) - Nov 2, 2019 - Abstract #SITC2019SITC_1307;
INO-5401 + INO-9012 with cemiplimab has an acceptable safety profile, is immunogenic and is potentially efficacious in patients with newly-diagnosed GBM. This combination is promising; survival results will be updated next year.
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment change, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Oct 1, 2019
P1/2, N=35, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
This combination is promising; survival results will be updated next year. N=85 --> 35
- | rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment closed, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Aug 14, 2019
P1/2, N=85, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
N=85 --> 35 Recruiting --> Active, not recruiting
- || rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment closed, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Mar 29, 2019
P1/2, N=52, Active, not recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Jun 25, 2018
P1/2, N=85, Recruiting, Sponsor: Inovio Pharmaceuticals
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- ||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
Enrollment open, Combination therapy: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Jun 18, 2018
P1/2, N=52, Recruiting, Sponsor: Inovio Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1/2 trial, Combination therapy, Metastases: INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) - Apr 18, 2018
P1/2, N=85, Not yet recruiting, Sponsor: Inovio Pharmaceuticals
- ||||| rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
New P1/2 trial, Combination therapy, PD(L)-1 Biomarker, IO biomarker: INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) (clinicaltrials.gov) - Apr 8, 2018
P1/2, N=52, Not yet recruiting, Sponsor: Inovio Pharmaceuticals